Newsfeeds Archive - Spark Newswire

2 minute read

Movers
News

What’s Going On With FibroGen Stock Tuesday?

June 4, 2:27 PM

FibroGen Inc (NASDAQ:FGEN) shares are trading higher Tuesday morning after the company said the FDA cleared its Investigational New Drug (IND) of FG-3165. FibroGen also announced a new clinical trial supply agreement with Regeneron.

FGEN

3 minute read

Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

By Avi Kapoor

June 4, 5:50 AM

Shares of Healthequity Inc (NASDAQ:HQY) rose sharply in today’s pre-market trading as the company reported better-than-expected first-quarter financial…

ALBT

2 minute read

FibroGen Stock Is Surging After The Bell: What’s Going On?

By Adam Eckert

June 3, 4:48 PM

FibroGen shares are moving higher in Monday's after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) FG-3165. The company also announced a new clinical trial supply agreement with Regeneron.

FGEN

1 minute read

Movers

12 Health Care Stocks Moving In Monday’s After-Market Session

By Benzinga Insights

June 3, 4:31 PM

Gainers FibroGen (NASDAQ:FGEN) stock moved upwards by 24.4% to $1.53 during Monday’s after-market session. The market value of…

BGXX

1 minute read

FibroGen Inks Clinical Trial Supply Agreement With Regeneron Pharmaceuticals To Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 And FG-3175, In Combination With LIBTAYO In Upcoming Clinical Trials

By Benzinga Newsdesk

June 3, 4:09 PM

FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO® in patients with select solid tumorsFibroGen to evaluate FG-3175,

FGEN

4 minute read

Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session

By Avi Kapoor

May 7, 2:35 PM

Shares of Beyond, Inc. (NYSE:BYON) fell sharply during Tuesday’s session following weaker-than-expected quarterly results. BeyondÂ posted adjusted loss of…

ADTN

2 minute read

FibroGen Shares Climb On Strong Q1 Sales

By Erica Kollmann

May 7, 1:10 PM

FibroGen reported quarterly losses of 33 cents per share which missed the analyst consensus estimate of $(0.31) and represents a 59.26% increase year-over-year. Quarterly sales clocked in at $55.902 million which beat the analyst consensus estimate of $36.666 million by 52.46% and is a significant increase over sales of $36.161 million from the same period last year.

FGEN